10:35 AM EST, 01/28/2025 (MT Newswires) -- BioAge Labs ( BIOA ) said Tuesday it terminated the development of azelapra after elevated levels of certain liver enzymes were recorded in the blood of some patients in a phase 2 clinical study for obesity.

The company said it is developing structurally distinct APJ agonists and plans to finalize a development candidate by the end of 2025.

BGE-102 is under development for the treatment of neuroinflammation and phase 1 single ascending dose data is expected by the end of the year, BioAge ( BIOA ) said.

Price: 5.29, Change: -0.09, Percent Change: -1.58